Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B

被引:138
作者
Westland, CE [1 ]
Yang, HL [1 ]
Delaney, WE [1 ]
Gibbs, CS [1 ]
Miller, MD [1 ]
Wulfsohn, M [1 ]
Fry, J [1 ]
Brosgart, CL [1 ]
Xiong, S [1 ]
机构
[1] Gilead Sci Inc, Foster City, CA 94404 USA
关键词
D O I
10.1053/jhep.2003.50288
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Seven hundred nucleoside treatment-naive patients were enrolled in two phase 3 trials of adefovir dipivoxil. (ADV) for the treatment of chronic hepatitis B. To monitor for the emergence of potential adefovir resistance mutations over the first 48 weeks, all intent-to-treat patients (467 ADV-treated and 228 placebo patients) were included in a prospectively defined, treatment-blinded, virology substudy. The study protocol mandated genotypic analysis for all patients with detectable hepatitis B virus (HBV) DNA by Roche Amplicor polymerase chain reaction (PCR) at baseline and week 48, and in vitro phenotypic analyses for patients with conserved site substitutions in HBV polymerase or 1.0 log(10) or greater increase in HBV DNA from nadir. Paired sequences of the entire HBV reverse transcriptase were obtained for 271 ADV-treated and 227 placebo patients by using a sequencing method that detects down to 30% of minor species present within mixtures. Four substitutions (rtS119A, rtH133L, rtV214A, and rtH234Q) developed once each at conserved sites in HBV polymerase in 4 ADV-treated patients. Seven conserved site substitutions developed in 6 placebo patients. HBV mutants encoding the 4 substitutions that emerged in ADV-treated patients remained fully susceptible to adefovir in vitro. Furthermore, these 4 ADV-treated patients had HBV-DNA reductions of 3.3 to 5.9 log(10) copies/mL by week 48 with no rebound. All other substitutions occurred at very low frequencies (<1.6%) at polymorphic sites and were not associated with HBV-DNA increases in patients or adefovir resistance in vitro. In conclusion, no adefovir resistance mutations were identified in a large group of chronic hepatitis B patients treated with ADV for 48 weeks.
引用
收藏
页码:96 / 103
页数:8
相关论文
共 36 条
[1]   Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].
Allen, MI ;
Deslauriers, M ;
Andrews, CW ;
Tipples, GA ;
Walters, KA ;
Tyrrell, DLJ ;
Brown, N ;
Condreay, LD .
HEPATOLOGY, 1998, 27 (06) :1670-1677
[2]   Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study [J].
Benhamou, Y ;
Bochet, M ;
Thibault, V ;
Calvez, V ;
Fievet, MH ;
Vig, P ;
Gibbs, CS ;
Brosgart, C ;
Fry, J ;
Namini, H ;
Katiama, C ;
Poynard, T .
LANCET, 2001, 358 (9283) :718-723
[3]   Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro [J].
Cherrington, JM ;
Mulato, AS ;
Fuller, MD ;
Chen, MS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2212-2216
[4]   In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil [J].
Chin, R ;
Shaw, T ;
Torresi, J ;
Sozzi, V ;
Trautwein, C ;
Bock, T ;
Manns, M ;
Isom, H ;
Furman, P ;
Locarnini, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) :2495-2501
[5]   Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC) [J].
Das, K ;
Xiong, XF ;
Yang, HL ;
Westland, CE ;
Gibbs, CS ;
Sarafianos, SG ;
Arnold, E .
JOURNAL OF VIROLOGY, 2001, 75 (10) :4771-4779
[6]  
Delaney WE, 2002, HEPATOLOGY, V36, p373A
[7]  
Delaney WE, 2001, ANTIVIR CHEM CHEMOTH, V12, P1
[8]   Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus [J].
Delaney, WE ;
Edwards, R ;
Colledge, D ;
Shaw, T ;
Torresi, J ;
Miller, TG ;
Isom, HC ;
Bock, CT ;
Manns, MP ;
Trautwein, C ;
Locarnini, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1705-1713
[9]   Lamivudine as initial treatment for chronic hepatitis B in the United States [J].
Dienstag, JL ;
Schiff, ER ;
Wright, TL ;
Perrillo, RP ;
Hann, HWL ;
Goodman, Z ;
Crowther, L ;
Condreay, LD ;
Woessner, M ;
Rubin, M ;
Brown, NA .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (17) :1256-1263
[10]  
Foli A, 1996, ANTIVIR RES, V32, P91, DOI 10.1016/0166-3542(95)00985-X